Key information

🔎 Fund Overview

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. It is focused on translating insights from genetic epilepsies into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalances. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small molecule platform, which utilizes understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally precision therapies; and Solidus, is an antisense oligonucleotide (ASO) platform, which targets precision medicine discovery and development engine anchored on a proprietary, computational methodology. Its product candidates include PRAX-944, PRAX-562, PRAX-628 and PRAX-222.